Showing 2301-2310 of 10580 results for "".
Patient Portals
https://practicaldermatology.com/topics/practice-management/patient-portals/19113/Michael J. Sacopulos, JD, Founder and President of Medical Risk Institute (www.medriskinstitute.com), addresses the role, benefits, and potential pitfalls of patient portals.How to Deal with Hagglers and Other Tough Patients
https://practicaldermatology.com/topics/practice-management/how-to-deal-with-hagglers-and-other-tough-patients/19211/Michael J. Sacopulos, JD offers strategies for handling difficult patients and how to negotiate with hagglers.Hoya ConBio - The Medlite Peel
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-the-medlite-peel/19455/A specific patient case is demonstrated to show the outcome of using the Medlite as a laser peel. Valuable tips and suggestions are given by Dr. Brian Rubach.Hoya ConBio - Laser Assisted Hair Reduction
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-laser-assisted-hair-reduction/19461/Video demonstrations on the different settings to use for laser assisted hair reduction.BroadBand Light BBL - Patient Testimonials
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/broadband-light-bbl-patient-testimonials/19466/Patients describe their experience with sciton BroadBand Light (BBL).Treatment Approaches for Psoriatic Arthritis
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/treatment-approaches-for-psoriatic-arthritis/48809/Naeim T. Issa, MD, PhD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the Mediterranean Journal of Rheumatology article “Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective.”June Issue: Melanoma Updates - Epidemiology, Diagnostics, and Treatment
https://practicaldermatology.com/issues/may-june-2025/melanoma-updates-epidemiology-diagnostics-and-treatment/35917/In this article, we review the latest changes in melanoma incidence and mortality, highlight key disparities among minority populations, and summarize emerging trends in technology and treatment that are reshaping the future of melanoma care.FDA Approval for Delgocitinib
https://practicaldermatology.com/series/c-suite-chats/fda-approval-for-delgocitinib/36650/Robert Spurr, EVP, North America for LEO Pharma, discusses the importance of an FDA-approved option for treating moderate-to-severe chronic hand eczema in adults.DWTV Extra: New Tapinarof Data for AD
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-new-tapinarof-data-for-ad/33940/Linda Stein Gold, MD, discusses the results from the Phase 3 ADORING 3 open-label, long-term extension study evaluating tapinarof cream, 1% once daily in children as young as 2 and adults with atopic dermatitis, presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in OrlandoThe Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succe